You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NS 8593 hydrochloride
Selective KCa2 (SK) channel negative modulator; inhibits SK channel currents (Kd values are 0.42, 0.6 and 0.73 μM for SK1, SK2 and SK3 respectively at 0.5 μM Ca2+). Exhibits selectivity for SK channels over KCa1.1 (BK), KCa3.1 (IK), Kv, Nav and Cav channels. Inhibits afterhyperpolarization in hippocampal slices.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 299.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.34 mL||16.68 mL||33.36 mL|
|5 mM||0.67 mL||3.34 mL||6.67 mL|
|10 mM||0.33 mL||1.67 mL||3.34 mL|
|50 mM||0.07 mL||0.33 mL||0.67 mL|
References are publications that support the biological activity of the product.
Strøbaek et al (2006) Inhibitory gating modulation of small conductance Ca2+-activated K+ channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hip Mol.Pharmacol. 70 1771 PMID: 16926279
Sørensen (2008) Synthesis and structure-activity relationship studies of 2-(N-substituted)-aminobenzimidazoles as potent negative gating modulators of small conductance Ca2+-activated K+ channels. J.Med.Chem. 51 7625 PMID: 18998663
Jenkins et al (2011) Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of KCa2 channels. Mol.Pharmacol. 79 899 PMID: 21363929
If you know of a relevant reference for NS 8593 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: NS 8593 hydrochloride, NS 8593 hydrochloride supplier, NS8593, hydrochloride, selective, Kca2, SK, small, channels, conductance, calcium, ca2+, activated, potassium, K+, modulators, inhibits, inhibitors, Ca2+-Activated, Potassium, Channels, 4597, Tocris Bioscience
1 Citation for NS 8593 hydrochloride
Citations are publications that use Tocris products. Selected citations for NS 8593 hydrochloride include:
Tian et al (2018) Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels. J Cell Mol Med 22 6327 PMID: 30338939
Do you know of a great paper that uses NS 8593 hydrochloride from Tocris? Please let us know.
Reviews for NS 8593 hydrochloride
Average Rating: 5 (Based on 1 Review.)
Have you used NS 8593 hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Product was used to study SK channel activity. Shows channel blocking activity and reduced Calcium activated opening. Great product, performs well and stable.
The product was dissolved in DMSO. Sterile DMSO must be used for sterile cell culture studies.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.